BioSpace News Archive

NanoString Technologies, Inc. announced preliminary operational and financial results for the quarter ended March 31, 2020, and outlined the company’s response to the COVID-19 pandemic and the ongoing impact on operations.

P4 Diagnostix® Network has announced they have submitted their LDT for COVID-19 based upon the FDA EUA approved ThermoFisher TaqPath RT-PCR COVID-19 Combo Kit.

GlycoMimetics, Inc. announced that the compensation committee of the Company’s Board of Directors approved the grant on April 1, 2020 of non-qualified stock option awards to purchase an aggregate of 40,600 shares of its common stock to two new employees.

Luminex Corporation announced 1st quarter 2020 revenues of just over $90 million, up approximately 10% over the 1st quarter of 2019 and approximately 8% above the top end of its previously communicated 1st quarter revenue guidance range of $82 to $84 million.

Timber Pharmaceuticals LLC announced the company has been awarded the second tranche of $500,000 of the $1.5 million grant from the U.S. Food & Drug Administration Office of Orphan Products Development Orphan Products Clinical Trials Grants Program after reaching certain clinical milestones in the development of TMB-001.

Engine Capital Withdraws Director Nomination Notice For 2020 Annual Meeting of Stockholders

Company to Report First Quarter 2020 Results and Host Conference Call and Webcast on May 5, 2020

BELLUS Health Inc. announced that it has completed patient dosing in its Phase 2 RELIEF clinical trial of BLU-5937 for the treatment of refractory chronic cough, with 52 patients completing treatment.

“Would you stay at home if you held the medicine that would save your neighbor’s life?” asked Dr. Charles Runels, MD, the inventor of the Vampire Facelift® procedure..

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic